You are here: Home: Audio Program Guide: CCU for Surgeons 1 | 2006: Download Audio
Go to interview with John L Marshall, MD Go to interview with Lawrence D Wagman, MD Go to interview with Robert A Wolff, MD Go to interview with W Douglas Wong, MD
To listen to individual tracks, click the on the track you wish to listen to. To download tracks, right-click on the one you wish to download.

 

John L Marshall, MD Chief, Hematology and Oncology Director of Developmental Therapeutics and GI Oncology Lombardi Comprehensive Cancer Center Georgetown University Washington, DC
	Click here to download the entire interview
Track 1	Introduction
Track 2	Curability of metastatic disease with surgical resection
Track 3	Biologic rationale for surgical resection of metastatic disease
Track 4	Management of a synchronous primary lesion and liver metastases
Track 5	Timing of surgery following bevacizumab
Track 6	Radiofrequency ablation of liver metastases
Track 7	Intrahepatic infusion of chemotherapy
Track 8	Aggressive surveillance for earlier diagnosis of metastatic disease
Track 9	Importance of adequacy of lymph node sampling for disease staging
Track 10	Adjuvant chemotherapy for patients with Stage II disease
Track 11	Incorporating biologics into adjuvant clinical trials
Track 12	Duration and tolerability of adjuvant bevacizumab
Track 13	Tolerability and side effects of oxaliplatin
Track 14	Potential advantage of the oral fluoropyrimidine prodrug capecitabine in the adjuvant setting

Lawrence D Wagman, MD Chair, Division of Surgery Director, Department of General Oncology Surgery Section Head, Hepatobiliary Section City of Hope National Medical Center Duarte, California
	Click here to download the entire interview
Track 1	Introduction
Track 2	NSABP-C-09 trial: CAPOX with or without hepatic arterial infusion of FUDR for patients with resected or ablated liver metastases
Track 3	Strategies to improve quality of hepatic arterial infusion in NSABP-C-09
Track 4	Rationale for not including bevacizumab in NSABP-C-09
Track 5	Rationale for the use of capecitabine versus 5-FU in NSABP-C-09
Track 6	Selection of patients for more aggressive surveillance to identify metastatic disease earlier
Track 7	Clinical use of hepatic arterial infusion
Track 8	Radiofrequency ablation versus surgical resection for hepatic lesions
Track 9	Considerations in the selection of a colorectal cancer surgeon
Track 10	Management of a synchronous primary tumor and liver metastases
Track 11	NSABP-R-04: Preoperative radiation therapy and either capecitabine or fluorouracil with or without oxaliplatin
Track 12	Importance of the number of lymph nodes examined when staging colon cancer
Track 13	Adjuvant chemotherapy for patients with Stage II disease
Track 14	Potential benefit of capecitabine versus 5-FU for elderly patients
Track 15	Referring patients with Stage II disease to medical oncologists
Track 16	Patient perspectives on adjuvant chemotherapy for colorectal cancer

Robert A Wolff, MD Associate Professor of Medicine Deputy Chairman for Clinical Affairs Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center
	Click here to download the entire interview
Track 1	Introduction
Track 2	Importance of adequate lymph node dissection and pathology review
Track 3	Rationale for trials examining the role of bevacizumab in the adjuvant setting
Track 4	Selection of capecitabine as adjuvant chemotherapy
Track 5	Discussion of chemotherapy side effects with patients
Track 6	Side effects and tolerability of FOLFOX
Track 7	Benefits of preoperative chemoradiation therapy for rectal cancer
Track 8	Efficacy of neoadjuvant capecitabine versus infusional 5-FU for rectal cancer

W Douglas Wong, MD Chief, Colorectal Service Stuart H Q Quan Chair in Colorectal Surgery Memorial Sloan-Kettering Cancer Center New York, New York
	Click here to download the entire interview
Track 1	Introduction
Track 2	Endorectal ultrasound for primary staging of rectal cancer
Track 3	Timing of surgery following neoadjuvant bevacizumab
Track 4	Enhancing neoadjuvant therapy for rectal cancer using newer chemotherapy and biologic agents
Track 5	Selection of patients to receive local excision for rectal cancer following neoadjuvant therapy
Track 6	Quality control in rectal cancer surgery
Track 7	Patient preferences for sphincter-sparing surgery
Track 8	Use of diversion with rectal cancer surgery
Track 9	Laparoscopic surgery for colon and rectal cancer
Track 10	Surgical and pathological issues confounding the number of lymph nodes examined
Track 11	Criteria for referring colorectal cancer patients to a medical oncologist
Track 12	Tolerability of adjuvant chemotherapy for colorectal cancer
Track 13	Management of a synchronous primary tumor and liver metastases
Track 14	Clinical use of hepatic arterial infusion and radiofrequency ablation
Track 15	Patient preferences for capecitabine versus 5-FU
Track 16	Benefit of intensive surveillance for patients with colon cancer